Akorn, Inc. (NASDAQ:AKRX)‘s stock had its “hold” rating restated by research analysts at Piper Jaffray Companies in a research note issued to investors on Thursday. They currently have a $34.00 target price on the stock. Piper Jaffray Companies’ target price would suggest a potential upside of 1.92% from the company’s previous close.

A number of other research firms have also weighed in on AKRX. Zacks Investment Research raised shares of Akorn from a “sell” rating to a “hold” rating in a research note on Monday, May 8th. Royal Bank Of Canada set a $34.00 price objective on shares of Akorn and gave the company a “hold” rating in a research note on Tuesday, June 27th. TheStreet lowered shares of Akorn from a “b-” rating to a “c” rating in a research note on Tuesday, August 1st. Gabelli reaffirmed a “hold” rating on shares of Akorn in a research note on Tuesday, April 25th. Finally, BidaskClub lowered shares of Akorn from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Four analysts have rated the stock with a sell rating, nine have issued a hold rating and one has issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $28.56.

Shares of Akorn (NASDAQ:AKRX) opened at 33.36 on Thursday. The company has a market capitalization of $4.17 billion, a PE ratio of 33.70 and a beta of 1.36. Akorn has a 12 month low of $17.61 and a 12 month high of $34.00. The firm’s 50-day moving average is $33.55 and its 200 day moving average is $28.93.

TRADEMARK VIOLATION WARNING: This report was published by Watch List News and is owned by of Watch List News. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://www.watchlistnews.com/piper-jaffray-companies-reaffirms-hold-rating-for-akorn-inc-nasdaqakrx/1467754.html.

In other Akorn news, COO Bruce Kutinsky sold 40,000 shares of Akorn stock in a transaction dated Thursday, August 3rd. The shares were sold at an average price of $33.46, for a total value of $1,338,400.00. Following the sale, the chief operating officer now owns 317,480 shares of the company’s stock, valued at $10,622,880.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Brian Tambi sold 5,165 shares of Akorn stock in a transaction dated Friday, August 4th. The stock was sold at an average price of $33.37, for a total transaction of $172,356.05. The disclosure for this sale can be found here. 28.20% of the stock is owned by company insiders.

A number of hedge funds have recently made changes to their positions in the company. NEXT Financial Group Inc raised its stake in shares of Akorn by 990.9% in the first quarter. NEXT Financial Group Inc now owns 3,000 shares of the company’s stock valued at $100,000 after buying an additional 2,725 shares in the last quarter. Meadow Creek Investment Management LLC raised its stake in shares of Akorn by 8.3% in the first quarter. Meadow Creek Investment Management LLC now owns 4,368 shares of the company’s stock valued at $105,000 after buying an additional 336 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Akorn by 22.8% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,228 shares of the company’s stock valued at $108,000 after buying an additional 599 shares in the last quarter. Glen Harbor Capital Management LLC raised its stake in shares of Akorn by 8.3% in the first quarter. Glen Harbor Capital Management LLC now owns 5,304 shares of the company’s stock valued at $128,000 after buying an additional 408 shares in the last quarter. Finally, Victory Capital Management Inc. raised its stake in shares of Akorn by 17.6% in the second quarter. Victory Capital Management Inc. now owns 4,177 shares of the company’s stock valued at $140,000 after buying an additional 626 shares in the last quarter. 74.73% of the stock is currently owned by institutional investors and hedge funds.

Akorn Company Profile

Akorn Inc (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health.

Analyst Recommendations for Akorn (NASDAQ:AKRX)

Receive News & Ratings for Akorn Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.